Just caught wind of something interesting in the biotech space. Bioxytran announced their antiviral candidate ProLectin-M hit some solid milestones recently, and honestly it's a different approach than what we've seen before.

So here's what caught my attention - instead of the replication-blocking strategy that Paxlovid uses, these guys are going after viral entry itself with a galectin-blocking mechanism. Their March data showed a 16,800 mg/day dose cleared virus in 90% of patients by Day 5, which is pretty compelling. They ran a 39-person study to nail down this optimal dosing, and it actually held up well on the safety side too.

What's notable is they're now moving toward Phase 3, which is the big one. They're in talks with FDA and India's CDSCO to design what would be roughly a 408-person randomized trial. If Phase 3 goes well, this becomes their shot at full regulatory approval. The trial would test it on standard-risk COVID patients plus other viral infections like flu and RSV, measuring viral clearance or clinical improvement by Day 5.

The investment angle here is the stock has been trading pretty cheap - bouncing between $0.03 and $0.2 over the past year. Closed recently at $0.04, up about 6.5% on the news. Obviously Phase 3 trials are high-risk, high-reward situations, but if their entry-blocking mechanism actually delivers what they're claiming, it could be differentiated enough to matter. Worth keeping an eye on how Phase 3 progresses.